newsfilter
← Latest News
GlobeNewswire·

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March